Overview

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether IPX159 is safe and effective in treating symptoms of RLS in subjects with Restless Legs Syndrome.
Phase:
Phase 2
Details
Lead Sponsor:
IMPAX Laboratories, Inc.
Impax Laboratories, LLC